Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Colorcon
Boehringer Ingelheim
AstraZeneca
Baxter
Mallinckrodt
Johnson and Johnson

Last Updated: November 21, 2019

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR FINACEA

See Plans and Pricing

« Back to Dashboard

All Clinical Trials for FINACEA

Trial ID Title Status Sponsor Phase Start Date Summary
NCT01038869 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed Bayer Phase 4 2009-12-01 Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01038869 Efficacy and Safety Study of Finacea to Treat Acne Vulgaris and Post-Inflammatory Hyperpigmentation (PIH) Completed Derm Research, PLLC Phase 4 2009-12-01 Residual post-inflammatory hyperpigmentation (PIH)from acne is disturbing to individuals with skin of color. Finacea has been anecdotally known to be beneficial in resolving PIH related to acne vulgaris. However, it has not been clinically tested for this purpose. The current study will investigate the efficacy and safety of Finacea in the treatment of acne vulgaris and PIH.
NCT01139008 Split-Face Tolerability Comparison Between MetroGel® 1% Versus Finacea® 15% in Subjects With Healthy Skin Completed Galderma Laboratories, L.P. Phase 4 2010-06-01 The purpose of this study is to compare the tolerability of MetroGel® (metronidazole gel) 1% to Finacea® (azelaic acid) Gel 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01139047 Split-face Tolerability Comparison Between MetroGel® 1% vs Finacea® 15% in Subjects With Healthy Skin Completed Galderma Laboratories, L.P. Phase 4 2010-06-01 The purpose of this study is to compare the tolerability of MetroGel® 1% to Finacea® 15% in subjects with healthy skin applied according to product labeling for three weeks.
NCT01631656 Combination Gel and Vascular ND in Mild to Moderate Rosacea Completed Bayer N/A 2010-07-01 The purpose of this study is to compare efficacy and outcomes of treatment with azelaic acid (Finacea Gel) and Vascular ND:Yag laser therapy versus Vascular ND:Yag laser therapy alone via a split face study design in approximately ten to fifteen subjects with mild to moderate rosacea. We hypothesize that treatment of rosacea with combination azelaic acid (Finacea Gel) and Vascular ND:Yag laser therapy will lead to a greater improvement in lesion count, redness and telangiectasias compared to treatment with Vascular ND: Yag laser therapy alone.
NCT01631656 Combination Gel and Vascular ND in Mild to Moderate Rosacea Completed Wake Forest University Health Sciences N/A 2010-07-01 The purpose of this study is to compare efficacy and outcomes of treatment with azelaic acid (Finacea Gel) and Vascular ND:Yag laser therapy versus Vascular ND:Yag laser therapy alone via a split face study design in approximately ten to fifteen subjects with mild to moderate rosacea. We hypothesize that treatment of rosacea with combination azelaic acid (Finacea Gel) and Vascular ND:Yag laser therapy will lead to a greater improvement in lesion count, redness and telangiectasias compared to treatment with Vascular ND: Yag laser therapy alone.
NCT02120924 A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea Completed Actavis Inc. Phase 3 2013-07-01 The purpose of the study is to compare the safety and efficacy profiles of a generic Azelaic Acid Gel, 15% to the reference listed Finacea® (azelaic acid) Gel, 15% in the treatment of moderate facial rosacea.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for FINACEA

Condition Name

Condition Name for FINACEA
Intervention Trials
Rosacea 5
Skin Manifestations 2
Rosacea, Papulopustular 1
Post Inflammatory Hyperpigmentation 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for FINACEA
Intervention Trials
Rosacea 7
Skin Manifestations 2
Hyperpigmentation 1
Acne Vulgaris 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for FINACEA

Trials by Country

Trials by Country for FINACEA
Location Trials
United States 36
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for FINACEA
Location Trials
Texas 3
North Carolina 3
Florida 2
California 2
Kentucky 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for FINACEA

Clinical Trial Phase

Clinical Trial Phase for FINACEA
Clinical Trial Phase Trials
Phase 4 5
Phase 3 3
Phase 1 1
[disabled in preview] 1
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for FINACEA
Clinical Trial Phase Trials
Completed 8
Not yet recruiting 1
Recruiting 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for FINACEA

Sponsor Name

Sponsor Name for FINACEA
Sponsor Trials
Bayer 3
Derm Research, PLLC 2
Actavis Inc. 2
[disabled in preview] 5
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for FINACEA
Sponsor Trials
Industry 10
Other 5
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Dow
Medtronic
McKesson
Johnson and Johnson
Mallinckrodt

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.